<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144936</url>
  </required_header>
  <id_info>
    <org_study_id>VX09-985-101</org_study_id>
    <nct_id>NCT01144936</nct_id>
  </id_info>
  <brief_title>Study of VX-985 in Subjects With Chronic Hepatitis C</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV
      subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of
      VX-985.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (vital signs, 12-lead electrocardiograms, physical examinations, laboratory assessments, and adverse events)</measure>
    <time_frame>10-13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic parameters of VX-985</measure>
    <time_frame>10-13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA levels</measure>
    <time_frame>5-7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Panel 1: VX-985 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: VX-985 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: VX-985 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-985 or matching placebo</intervention_name>
    <description>low dose</description>
    <arm_group_label>Panel 1: VX-985 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-985 or matching placebo</intervention_name>
    <description>high dose</description>
    <arm_group_label>Panel 2: VX-985 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-985 or matching placebo</intervention_name>
    <description>dose TBD</description>
    <arm_group_label>Panel 3: VX-985 Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are male or females of non-childbearing potential aged 18 to 64
             years(inclusive) with a body mass index (BMI) between 18 and 32 (kg/m2)

          -  Certain subjects must agree to use acceptable contraceptive methods as specified in
             protocol

          -  Subjects who are treatment na√Øve and are infected with genotype 1 chronic hepatitis C

          -  Subjects must be in good health and have normal laboratory values as judged by
             investigator

          -  Subjects must not have clinically significant abnormal results for physical
             examination

        Exclusion Criteria:

          -  Subjects must not have received approved or experimental HCV therapy

          -  Subjects must not have evidence of hepatic decompensation: history of ascites, hepatic
             encephalopathy, or bleeding esophageal varices

          -  Subjects must not have any known history of other cause of significant liver disease
             including hepatitis B, drug or alcohol-related cirrhosis, etc

          -  Subjects must not be diagnosed with or have suspected hepatocellular carcinoma

          -  Subjects must not have histologic evidence of hepatic cirrhosis on any liver biopsy or
             test capable of detecting cirrhosis within the past 2 years

          -  Subjects with a known history or other evidence of severe retinopathy or clinically
             significant ophthalmological disorder

          -  Subjects must not have a history of any illness that might confound the results of the
             study or pose an additional risk in administering study drug(s) to the subject e.g.
             history of cardiovascular or central nervous system disease, ongoing psychiatric
             disorder, poorly controlled diabetes, etc

          -  Subject must not have taken any of the prohibited medications within the specified
             time before study start or take certain medications (including herbal supplements)
             during the study

          -  Subjects must not have a history of drug or alcohol abuse or addiction within 6 months
             before the start of dosing, or test positive for alcohol or drugs of abuse

          -  Subjects must not have donated or had a significant loss of blood within 56 days of
             the start of dosing, or donated more than 1 unit of plasma within 7 days before the
             start of dosing

          -  Subjects must not consume excessive amounts of caffeine

          -  Subjects must not have participated in a clinical study involving administration of
             either an investigational or a marketed drug within 2 months

          -  Subjects who are female and have a positive pregnancy test and/or who are considered
             to be of childbearing potential or are nursing.

          -  Subjects that have a female partner who is pregnant, nursing, or planning to become
             pregnant during the study or shortly after the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Mahnke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vertex Pharmaceuticals Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansas</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lisa Mahnke</name_title>
    <organization>Vertex Pharmaceuticals Incorporated</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

